What topics does this cannabis study cover?

This study covers research on: THC, Anxiety, Mental Health.

Where was this research published?

Published in Journal of molecular neuroscience : MN on October 12, 2026.

THC Anxiety Mental Health

Ultra-low-dose THC reduced anxiety-like behavior in stressed mice

Acute Ultra Low Dose THC Attenuates Anxiety-Like Behavior in a Mouse Model for Major-Depressive Disorder.

Journal of molecular neuroscience : MN • October 12, 2026 • Highly Relevant

🤖

AI Summary

The study asked whether acute, ultra-low-dose THC could reduce anxiety-like behavior in a mouse model of major depressive disorder. In mice exposed to chronic mild stress, the treatment was reported to ameliorate anxious behavior. The abstract reports the dose as 0.002 mg/kg, but provides no sample size, comparator details, or quantitative effect estimates, so the size of the observed change cannot be assessed here.

The researchers also used next-generation sequencing to examine changes in mRNAs related to neuronal differentiation and synaptic plasticity. They identified Elmod1 as a possible molecular mediator and reported involvement of glucocorticoid-related mRNAs. These findings are from mice and do not establish that THC treats anxiety or depression in people. This is an abstract-based summary; the abstract does not provide enough detail to assess the full methods or the strength of the evidence.

💡 Key Findings

In a chronic mild stress mouse model of major depressive disorder, acute THC at 0.002 mg/kg was reported to ameliorate anxiety-like behavior.

Good

70%

Sequencing results linked the treatment to changes in mRNAs related to neuronal differentiation and synaptic plasticity; the abstract identifies Elmod1 as a possible mediator of the reported anxiolytic effect.

Moderate

50%

The abstract also reports involvement of glucocorticoid-related mRNAs, but does not provide quantitative results or establish relevance to human treatment.

Moderate

50%

📄 Original Abstract

Major depressive disorder (MDD) is a prevalent psychiatric disorder, and is a leading cause of disability worldwide. Current treatments for MDD entail many side effects, and include a lag until the onset of therapeutic effects. The current hypotheses as for the etiology of MDD revolve around the monoamine hypothesis and the plasticity and neurodegeneration hypothesis. According to the latter, employing a neuroprotective treatment may help ameliorate depressive symptoms. Δ9-Tetrahydrocannabinol (THC) is the primary psychoactive component of the cannabis sativa plant. THC interacts with the endocannabinoid system, which was shown to be involved in the regulation of emotional states (e.g. anxiety) and stress through modulation of synaptic plasticity. Here, we show the potential of acute, ultra-low dose (0.002 mg/kg) THC in ameliorating anxious behavior in a chronic mild stress mouse model for MDD. We utilize next generation sequencing techniques to show the treatment's effect on neuronal differentiation and synaptic plasticity-related mRNAs, and specify Elmo domain containing 1 (Elmod1) as a molecular mediator of the observed anxiolytic effects. Moreover, we show the involvement of glucocorticoids-related mRNAs in the observed anxiolytic effect of acute, ultra-low dose THC.

Paper Type

📄 Research

Publication

Journal: Journal of molecular neuroscience : MN
Published: October 12, 2026
PMID: 42864498
DOI: 10.1007/s12031-026-02597-8

Authors (3)

Meitar Grad Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.
Hadas Volkov Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.
Noam Shomron Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel. nshomron@tauex.tau.ac.il.